Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear pore complex interacting protein family member B9 (NPIPB9) is a protein-coding gene in humans, part of a family of genes encoding nuclear pore complex-interacting proteins (NPIP family)[4][1][3]. This protein is associated with nuclear pore structures, potentially involved in nuclear envelope organization or transport between the nucleus and cytoplasm, although its precise biological functions remain unclear[3][1]. NPIPB9 is not classified as a receptor, enzyme, transporter, or other canonical therapeutic target[4]. Genetic variants have been weakly associated with conditions such as autism spectrum disorder and oxidative phosphorylation deficiency, but its direct disease role is not well-established[4]. The NPIP family is notable for segmental duplications, complicating analysis of its members and their roles[3]. There is no known interaction with drugs, established biomarker utility, or specific safety concerns associated with NPIPB9[4][1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear pore complex interacting protein family member B9 (NPIPB9).